Safety · 2026-06-25
Why States Are Banning Kratom: A 2026 Overview of Health Risks, State Laws, and Policy Trends
Source: Behavioral Health Group
Why it matters
As state-level kratom bans accelerate in 2026, patients and clinicians need a clear picture of the public health rationale — including the critical distinction between natural kratom leaf and concentrated 7-OH products.
The big picture
The kratom policy landscape is rapidly changing in 2026, with Tennessee banning the substance as of July 1, Kansas adding it to Schedule I, and New York passing legislation targeting synthetic kratom (7-OH). This overview, from a major U.S. outpatient addiction treatment provider, synthesizes FDA, DEA, and SAMHSA data to explain why state health officials are acting and what it means for patients who use kratom for pain management or opioid withdrawal.
Key findings
- Kratom is not FDA-approved to treat any medical condition — a key driver of state-level regulatory concern
- The FDA has warned about serious adverse events including liver toxicity, seizures, substance use disorder, and dependence
- Concentrated 7-hydroxymitragynine (7-OH) products carry heightened risk and represent the primary focus of many 2026 state bans
- Some people who use kratom regularly may experience withdrawal symptoms resembling mild opioid withdrawal when they stop
- States currently with statewide bans include Alabama, Arkansas, Indiana, Louisiana, Vermont, Wisconsin, and now Tennessee
- Other states are choosing age restrictions or labeling requirements instead of outright prohibition
What they say
Behavioral Health Group clinicians write that "when access changes suddenly, people who are dependent on kratom may experience withdrawal in the days and weeks after the ban, or may return to prescription opioids, illicit opioids such as fentanyl, or other substances to cope with symptoms if they do not have support."
Bottom line
State kratom bans are accelerating in 2026 largely driven by 7-OH products — and patients who rely on kratom for pain or withdrawal management need clinical support before legal access disappears.